fbpx

molecules of the month

SAR439859

oral sel. estrogen receptor degrader (SERD)

400 mg QD, in Ph. II for ER+/HER2- BC

from MTS of ER binders, opt. for degrd./antag.

Mol. Cancer Ther., Dec. 11, 2020

Sanofi, Vitry-sur-Seine, FR / Cambridge MA

Chemical structure of molecule SAR439859
1 min read

Sanofi oral selective estrogen receptor (ER) degrader (SERD)


request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.


already a member? log in: